Literature DB >> 8100914

Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen.

P Chocair1, J Duley, H A Simmonds, J S Cameron, L Ianhez, S Arap, E Sabbaga.   

Abstract

Early rejection can still complicate renal transplantation even with cyclosporin. We added low-dose allopurinol (25 mg on alternative days) to "triple" immunosuppression with cyclosporin, prednisolone, and azathioprine for twelve recipients of cadaver renal grafts. The controls were fifteen patients on triple therapy alone. Only one rejection episode occurred among the allopurinol-treated patients, whereas eleven controls had rejections (seven with more than one episode). Allopurinol may be toxic when combined with azathioprine, yet the bone marrow tolerated the new regimen well. As expected, reduction of the azathioprine dose was necessary in the treated group.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100914     DOI: 10.1016/0140-6736(93)91287-v

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

Review 1.  Clinically relevant drug-drug interactions in oncology.

Authors:  H L McLeod
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

2.  Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD.

Authors:  Shail M Govani; Peter D R Higgins
Journal:  J Crohns Colitis       Date:  2010-03-21       Impact factor: 9.071

3.  Low dose thiopurine and allopurinol co-therapy results in significant cost savings at a district general hospital.

Authors:  Suranga Dharmasiri; Hannah Dewhurst; Heather Johnson; Sean Weaver; Simon McLaughlin
Journal:  Frontline Gastroenterol       Date:  2014-11-07

4.  Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease.

Authors:  Miles P Sparrow
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-07

5.  Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.

Authors:  Ivanka Curkovic; Katharina M Rentsch; Pascal Frei; Michael Fried; Gerhard Rogler; Gerd A Kullak-Ublick; Alexander Jetter
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

Review 6.  Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature.

Authors:  T N Witte; A L Ginsberg
Journal:  Can J Gastroenterol       Date:  2008-02       Impact factor: 3.522

Review 7.  Use of thiopurines in inflammatory bowel disease.

Authors:  Pascal Frei; Luc Biedermann; Ole Haagen Nielsen; Gerhard Rogler
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

8.  Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.

Authors:  Sandra Bohn Thomsen; Kristine Højgaard Allin; Johan Burisch; Camilla Bjørn Jensen; Susanne Hansen; Lise Lotte Gluud; Klaus Theede; Marianne Kiszka-Kanowitz; Anette Mertz Nielsen; Tine Jess
Journal:  United European Gastroenterol J       Date:  2019-08-03       Impact factor: 4.623

9.  Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction.

Authors:  Frank Hoentjen; Stephen B Hanauer; Nanne K de Boer; David T Rubin
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

10.  Allopurinol reduces antigen-specific and polyclonal activation of human T cells.

Authors:  Damián Pérez-Mazliah; María C Albareda; María G Alvarez; Bruno Lococo; Graciela L Bertocchi; Marcos Petti; Rodolfo J Viotti; Susana A Laucella
Journal:  Front Immunol       Date:  2012-09-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.